PEG-MGF
PerformancePreclinicalAlso known as: Pegylated Mechano Growth Factor, PEGylated IGF-1 Ec, MGF, Mechano Growth Factor, IGF-1 splice variant
PEG-MGF (Pegylated Mechano Growth Factor) is a synthetic, PEGylated form of Mechano Growth Factor (MGF) — an alternatively spliced variant of IGF-1 produced locally in muscle and other tissues in response to mechanical loading or damage. MGF differs from systemic IGF-1 in that it has a unique E-domain peptide (the Ec peptide, or MGF peptide) that activates satellite cells (muscle stem cells) rather than IGF-1 receptor signaling.
Overview
At A Glance
PEG-MGF is the PEGylated form of Mechano Growth Factor (MGF), a synthetic peptide corresponding to the C-terminal 24 amino acids of the unique E-domain of IGF-1Ec, an alternatively spliced variant of the IGF-1 gene expressed in skeletal muscle after mechanical loading or damage. …
Overview
PEG-MGF (Pegylated Mechano Growth Factor) is a synthetic, PEGylated form of Mechano Growth Factor (MGF) — an alternatively spliced variant of IGF-1 produced locally in muscle and other tissues in response to mechanical loading or damage. MGF differs from systemic IGF-1 in that it has a unique E-domain peptide (the Ec peptide, or MGF peptide) that activates satellite cells (muscle stem cells) rather than IGF-1 receptor signaling. Pegylation (attachment of polyethylene glycol chains) dramatically extends MGF's plasma half-life from minutes to approximately 24 hours, enabling systemic administration in research protocols. PEG-MGF is researched primarily for its muscle satellite cell activation, tissue repair, and recovery applications.
Chemical Information
IUPAC Name
Not yet available
CAS Number
Not yet available
Molecular Formula
Not yet available
Molecular Mass
Free peptide approximately 2,867-2,868 Da (24-aa MGF E-peptide). The total mass of PEG-MGF is greater and is not standardized - it depends on the size of the attached PEG chain.
Amino Acid Sequence
Dosing & Protocols
Unlock Dosing Protocols
Free account gets you:
- View beginner, intermediate & advanced protocols
- See weight-based dosing calculations
- Access cycle length & frequency data
2,800+ researchers already in
Research
Unlock Research Data
Free account gets you:
- Browse PubMed study summaries
- See clinical trial phases & results
- Access mechanism of action details
2,800+ researchers already in
Interactions
Interaction and contraindication data is being compiled for PEG-MGF. Check back soon.
General Safety Note
Always consult a qualified healthcare professional before combining research compounds. Interactions may exist that are not yet documented.
$39.00
$19.5000
1
1
vial
Tracking since Apr 22, 2026 · 1 data point
Vendors Selling PEG-MGF
How we score these vendors
Every supplier above is graded 0–100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank.
Related Compounds
View AllITPP
PerformancePreclinicalITPP (myo-inositol trispyrophosphate, sometimes written myo-inositol tripyrophosphate or OXY111A in NormOxys trial documents) is a small-molecule allosteric effector of hemoglobin designed to increase the amount of oxygen red blood cells release to tissues.
SLU-PP-332
PerformancePreclinicalSLU-PP-332 is the first-generation synthetic pan-agonist of the estrogen-related receptors (ERRα, ERRβ, ERRγ) developed by the laboratory of Thomas Burris at Saint Louis University and reported in a landmark 2023 publication that established ERR pan-agonism as a pharmacologically tractable exercise-mimetic drug mechanism.
View Full Dosage Guide →
Protocols, calculator & safety for PEG-MGF
Research Score
0 PubMed studies
Quality Indicators
Data Completeness
63%Quick Facts
Half-Life
Native MGF: very short (minutes) due to rapid proteolysis. PEG-MGF: PEGylation is intended to extend this substantially (community estimates up to roughly 1 day), but there are no published human pharmacokinetic data to confirm a specific value.
Molecular Weight
Free peptide approximately 2,867-2,868 Da (24-aa MGF E-peptide). The total mass of PEG-MGF is greater and is not standardized - it depends on the size of the attached PEG chain.
Administration
Subcutaneous, Intramuscular, Intravenous
Trial Phase
Preclinical
Safety Profile
Common Side Effects
- • Injection-site reactions (redness, itching, swelling)
- • Post-injection fatigue or lethargy (anecdotal)
- • No controlled human data - tolerability is not established
Research Disclaimer
This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.
Frequently Asked Questions
What is PEG-MGF used for in research?
PEG-MGF (Pegylated Mechano Growth Factor) is a synthetic, PEGylated form of Mechano Growth Factor (MGF) — an alternatively spliced variant of IGF-1 produced locally in muscle and other tissues in response to mechanical loading or damage. MGF differs from systemic IGF-1 in that it has a unique E-domain peptide (the Ec peptide, or MGF peptide) that activates satellite cells (muscle stem cells) rather than IGF-1 receptor signaling. Pegylation (attachment of polyethylene glycol chains) dramatically extends MGF's plasma half-life from minutes to approximately 24 hours, enabling systemic administration in research protocols. PEG-MGF is researched primarily for its muscle satellite cell activation, tissue repair, and recovery applications.
What forms does PEG-MGF come in?
PEG-MGF is available in vial form.
How much does PEG-MGF cost?
Prices start at $39.00 across 1 verified vendor.
How do I compare PEG-MGF vendors?
Compare prices, payment methods, shipping, and COA scores across 1 vendor.
Research Tools
Related Compounds
View AllITPP
PerformancePreclinicalITPP (myo-inositol trispyrophosphate, sometimes written myo-inositol tripyrophosphate or OXY111A in NormOxys trial documents) is a small-molecule allosteric effector of hemoglobin designed to increase the amount of oxygen red blood cells release to tissues.
SLU-PP-332
PerformancePreclinicalSLU-PP-332 is the first-generation synthetic pan-agonist of the estrogen-related receptors (ERRα, ERRβ, ERRγ) developed by the laboratory of Thomas Burris at Saint Louis University and reported in a landmark 2023 publication that established ERR pan-agonism as a pharmacologically tractable exercise-mimetic drug mechanism.
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Reconstitution math, concentration charts, half-lives, and vendor trust tiers. The reference we wish we had on day one.
